Member Info for Energyshares

Now that Avacta have decided to keep control of its lead drug AVA6000 and take it to market .
Questions raised can they do it.

Just look at CV’s of Therapeutics leadership team.
Neil Bell
Neil has over 30 years’ experience in the drug development industry, having held senior positions in global pharmaceutical companies and innovative biotechs. In his role as Head of Global Clinical Operations for Teva Pharmaceuticals, Neil led an international team responsible for the delivery of clinical programmes in neurology, autoimmune and oncology therapeutic areas.
Following this period at Teva, Neil joined Daichi-Sankyo as Head of Clinical Operations where he led the clinical operations team through early and late stage development activities across cardiovascular, pain and oncology, and was responsible for building an effective drug development organisation in Europe serving the global clinical programmes and leading to the successful global approval of Edoxaban.

Fiona McLaughlin

Fiona McLaughlin is a highly experienced oncology drug developer, bringing over 25 years’ experience in research and translational drug development in the pharmaceutical and biotech sectors, Fiona started her career at GlaxoSmithKline, Other roles include Head of Biology at TopoTarget A/S, where she was responsible for the pre-clinical development of belinostat which went on to gain FDA approval to treat peripheral T-cell lymphoma. Most recently, Fiona was Vice President of New Opportunities at Algeta ASA (acquired by Bayer), a Norwegian biotech developing alpha radio-pharmaceuticals, that gained FDA approval of Xofigo to treat castration resistant prostate cancer.
Fiona has also gained broad experience during her career as a Consultant, providing scientific and strategic advice to biotechs, Not-for-Profit Organisations, and Venture Capitalists in UK, Europe, USA and Australia, including helping drive oncology strategy at the CRUK/AstraZeneca Alliance Laboratory.

55 years of experience between and two very connected individuals.

Onwards Avacta.
GLA

Avacta lead investigator invited to talk about Cytotoxic anti-cancer therapy at the official opening of the White City Labs.

Conventional anticancer chemotherapy is generally thought to act through selective killing of tumor cells or by irreversibly arresting their growth. Cytotoxic drugs interfere with DNA synthesis, or produce chemical damage to DNA, ultimately leading to tumor cell death.

Plus FDA have seen biopsies for OOD approval .

Rippers it works ……. ;)

Started in his Garage….

In the roughly 25 years since its IPO, Amazon has generated a total return of 199,332%, more than any other tech stock in the past 30 years. In fact, $10,000 invested in AMZN stock in 1997 would now be worth $19.9 million.

Started in a office above a Chippy in Wetherby….

You never know could get to £200 ex Chin-ah….

Avacta’s LTH’s some still under water by £1.80

How this plays out with positive results in the next few weeks,which camp are you in.

1. Rise above all time highs hitting £3.00 + then cash out.

2. You have a SP target then cash out.

3. Wait for a takeover then cash out.

I’m waiting for Number 3,because I dont think Large Pharma will let little Avacta keep their IP.

Looks like Bad Gnashers and his gang have finally given up, they are just trying to exit ASAP before they are wiped out.

Come on AS drop that licence RNS

Go Kenny Rogers

Just a Blip,
Happy 10000 days without a trophy Rippers ;)

Thanks nbastian,
We have Professor James Spicer Avacta SCIENTIFIC ADVISORY BOARD.
Who advises Avacta saying in a interview just 2 months ago.He would stop a trial which is actually not doing what it should, to discontinue its development as soon as possible. Before too many patients are exposed to an ineffective drug, and before too much money is wasted trying to develop it.

442 days

I will say again It Bloody works…..

33:10 on the video if anyone looking for comment.

Professor James Spicer
Avacta
SCIENTIFIC ADVISORY BOARD.

442 days into the trial when a member of Avacta SCIENTIFIC ADVISORY BOARD

In a article for BMJ as role model. Published on:
24 Aug 2022.

Makes a comment like this:

If you're working in a small company that's only got one product, sometimes you need partners like us who have a portfolio of interests, who can really give the bad news that a drug isn't going anywhere. 
We need to stop it, and that's explicitly an intention of early phase, Phase I trials. One major contribution we can make is to take a drug which is actually not doing what it should, to discontinue its development as soon as possible. Before too many patients are exposed to an ineffective drug, and before too much money is wasted trying to develop it.

It Bloody Works…….

https://www.bmj.com/careers/article/professor-james-spicer-professor-of-experimental-cancer-medicine-king-s-college-london

AS I mean Nanomat
Great post….

Few more weeks….,,

Craves more attention than Putin.

This article says it all for small stocks,
But Avacta will soon be pushing for FTSE 100 place
Onwards Avacta
https://www.morningstar.co.uk/uk/news/105769/investing-in-small-mid-and-large-cap-stocks.aspx

Why would Professor Udai Banerji take time out from his cancer clinics and turn up for a free buffet and give a speech about Pre Cision platform if AVA6000 was not working…….

Takeda, Merck, Novartis,
On the attack

Bristol-Myers Squibb and Boehringer Ingelheim GSK
In midfield

Gravestone teeth,Jupiter, Brontë on the defence.

Merchant Banker in Goal

Dr. Bachovchin is the inventor on 46 issued US patents, including reach-through patents covering the field of DPP-IV inhibitors for treating diabetes, a $10B market. This patent has been licensed by Merck, Novartis, Bristol-Myers Squibb and Boehringer Ingelheim

You can imagine these 4 companies above:
Hey Bill if you manage to get that FAPa working on cancer we will all be back for licences. :)

The up and coming science day is not the first Avacta have held.
They held one 4 years ago
and guess who was presenting: Professor Bill Bachovchin
Let’s hope it’s his big reveal this year.

Avacta London Science Day
Mon, 17th Dec 2018 07:00
RNS Number : 6002K
Avacta Group PLC
17 December 2018
 
 
 
 
17 December 2018
Avacta Group plc
("Avacta" or "the Group" or "the Company")
 
Avacta London Science Day
Avacta to hold a London Science Day with plenary presentation by
Josep Tabernero, President of ESMO and Head of the VHIO, Barcelona
 
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that it will host a Science Day, in London, on the morning of 14 February 2019, focusing on the rapidly changing nature of oncology treatment being brought about by immunotherapies and the role that the Affimer therapeutic platform is playing in this shift in the therapeutic paradigm.
 
The Group is delighted to announce that Dr Josep Tabernero, President of the European Society for Medical Oncology and Head of the Val d'Hebron Institute of Oncology, Barcelona, will give the plenary presentation reviewing the progress that has been made in cancer immunotherapies and the challenges that still remain.
 
Professor Bill Bachovchin, Professor of Molecular and Chemical Biology at Tufts University School of Medicine will discuss the potential for the revolutionary, immuno-oncology active, drug conjugate platform being developed in collaboration between Avacta and Tufts.

Dr. Bachovchin is a Professor of Biochemistry at Tufts University School of Medicine, where he has served as a faculty member for more than 28 years. Dr. Bachovchin is a world leader in the area of boronic acid chemistry and enzyme biochemistry. Dr. Bachovchin's work has led to the discovery and design of several candidate drugs. He has Co-Founded several biotech companies including Arisaph Pharmaceuticals, Point Therapeutics Inc and Bach Biosciences
Dr. Bachovchin is the inventor on 46 issued US patents, including reach-through patents covering the field of DPP-IV inhibitors for treating diabetes, a $10B market. This patent has been licensed by Merck, Novartis, Bristol-Myers Squibb and Boehringer Ingelheim. In addition three drugs first designed, synthesized and characterized in Dr. Bachovchin's laboratory at Tufts University School of Medicine have been advanced into human clinical trials.
Dr. Bachovchin completed his postdoctoral work with J.D. Roberts at California Institute of Technology and at Harvard Medical School. Prior to his Postdoctoral Work, Dr. Bachovchin received his Ph.D. in Chemistry from California Institute of Technology and his B.S. from Wake Forest University.

Don’t know if this has been shared before dated June 2022
Shows the growing advantages of affimers over antibodies.

https://pubmed.ncbi.nlm.nih.gov/35426494/

Takeda’s board must be locked in a room wondering how many noughts to add to the licence bid,to secure the rights after reading this paragraph from RNS.

In the case of Velcade, there are significant side effects such as peripheral neuropathy which has limited its approval, principally in treating multiple myeloma.

A potentially safer proteasome inhibitor, such as AVA3996, could WIN SIGNIFICANT MARKET SHARE for the treatment not only of multiple myeloma but also could be used to treat solid tumours, such as pancreatic cancer. Pancreatic cancer exhibits the HIGHEST LEVEL of FAP activity of any solid tumour and therefore a FAPa-activated drug could have significant potential in this area of high unmet need.